MedTrace Logo

Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors

NCT03326973 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 107

Last updated 2020-12-17

No results posted yet for this study

Summary

To identify and describe long-term quality of life (QOL) issues in patients with metastatic melanoma treated with checkpoint inhibitors who achieved cancer control for a minimum of 12 months and remain on maintenance checkpoint inhibitor therapy.

Conditions

Interventions

BEHAVIORAL

EuroQoL EQ-5D-3L

Overall QOL

BEHAVIORAL

EORTC QLQ-C30

General symptoms; physical, role, emotional, cognitive, and social functioning scales; fatigue, nausea/vomiting , and pain scales

OTHER

PRO-CTCAE

Additional potential immune-specific symptoms

BEHAVIORAL

Fatigue severity score questionnaire

Fatigue severity

BEHAVIORAL

The COST

Financial toxicity; satisfaction with ability to work

BEHAVIORAL

Physician information

Details on outside health providers

Sponsors & Collaborators

Principal Investigators

  • Deborah Korenstein, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-25
Primary Completion
2020-12-14
Completion
2020-12-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03326973 on ClinicalTrials.gov